Today’s Forbes Daily covers Eli Lilly’s historic loss, the new GPT-5 for OpenAI’s ChatGPT, reactions to Instagram’s new map ...

Stock futures were rising again on the eve of another tariff deadline as investors juggled strong earnings with more signs of U.S. economic weakness. Shares closed in the red Tuesday after the ISM ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and named a new CEO.

Novo Nordisk has named Maziar Mike Doustdar, currently the compan | Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar steps into the role succeeding Lars Fruergaard Jorgensen, effective Aug. 7 ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

Novo Nordisk’s first-mover advantage in this space with over 33 million patient-years of clinical data for semaglutide. This is a moat that is difficult to replicate by competitors.

Shares in Novo Nordisk NOVO.B0.16%increase; green up pointing triangle plunged after it cut its guidance, a result from the company losing its lead in the booming market for weight-loss drugs ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The ...